Controlled-release capsules (named brand I and II) containing caffeine, available on the Brazilian and US market as dietary supplements, were assessed following the criteria described by the United States Pharmacopeia. The capsules were evaluated by average weight, caffeine content, disintegration, and dissolution tests. Test results for all capsules met the acceptance criteria for these tests, with the exception of the dissolution of brand I capsules. The release rate of an active pharmaceutical ingredient (API) from a dosage form, measured by a dissolution test, is one of the fundamental parameters leading to the formulation's feasibility. The dissolution test is not mandatory to approve a dietary supplement in Brazilian and US markets. This study highlights the importance of evaluating these products by means of a performance test, such as dissolution, using products containing caffeine as case study.